FGF-19 Activators
FGF-19, a member of the fibroblast growth factor (FGF) family, functions as an endocrine signaling molecule primarily involved in the regulation of bile acid metabolism and lipid homeostasis. Produced mainly in the ileum of the small intestine, FGF-19 acts as a key mediator in the enterohepatic signaling axis, coordinating the response to dietary intake and bile acid levels. Upon secretion, FGF-19 travels through the bloodstream and binds to its specific receptor, FGFR4, expressed predominantly in hepatocytes. This binding event triggers a cascade of intracellular signaling pathways that culminate in the modulation of gene expression related to bile acid synthesis and lipid metabolism.
Activation of FGF-19 signaling is initiated by the interaction between FGF-19 and its receptor FGFR4, leading to receptor dimerization and autophosphorylation of tyrosine residues in the intracellular domains. Subsequently, activated FGFR4 recruits and phosphorylates intracellular adaptor proteins such as FGFR substrate 2α (FRS2α), facilitating the activation of downstream signaling pathways, including the Ras-MAPK and PI3K-Akt pathways. These signaling cascades converge on the regulation of gene expression involved in bile acid synthesis and lipid metabolism, leading to the suppression of bile acid production and promotion of lipid oxidation and storage. Overall, the activation of FGF-19 represents a critical physiological mechanism for maintaining bile acid homeostasis and lipid balance in response to dietary and metabolic cues.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW 0742 | 317318-84-6 | sc-203991 sc-203991A | 10 mg 50 mg | $194.00 $831.00 | 11 | |
PPAR-β/δ agonist that activates FGF-19 through the PPAR-β/δ pathway. Induces FGF-19 expression by binding to PPAR-β/δ receptors, leading to downstream activation. | ||||||
GW501516 | 317318-70-0 | sc-202642 sc-202642A | 1 mg 5 mg | $82.00 $179.00 | 28 | |
PPAR-δ agonist influencing FGF-19 activation via the PPAR-δ pathway. Activates FGF-19 expression by interacting with PPAR-δ receptors, modulating downstream signaling cascades. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
JMJD3 inhibitor indirectly activating FGF-19. By inhibiting JMJD3, GSK-J4 leads to increased H3K27me3 levels, influencing downstream pathways that culminate in FGF-19 activation. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Adenylyl cyclase activator increasing cAMP levels and activating the PKA pathway, leading to FGF-19 activation. Enhances FGF-19 expression by modulating downstream cascades connected to the PKA pathway. | ||||||
GSK 2334470 | 1227911-45-6 | sc-364501 sc-364501A | 10 mg 50 mg | $199.00 $1165.00 | 1 | |
SIK3 inhibitor activating FGF-19 through the LKB1/AMPK pathway. By inhibiting SIK3, GSK-2334470 promotes LKB1/AMPK activation, ultimately resulting in FGF-19 expression and activation. | ||||||
12β-Hydroxydigitoxin | 20830-75-5 | sc-213604 sc-213604A | 1 g 5 g | $143.00 $694.00 | ||
By inhibiting Na+/K+ ATPase, 12β-Hydroxydigitoxin influences cellular ion concentrations, modulating downstream pathways that lead to FGF-19 activation. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1/2 inhibitor indirectly activating FGF-19. By inhibiting JAK1/2, Ruxolitinib affects the JAK/STAT pathway, leading to downstream activation of signaling events associated with FGF-19. | ||||||
Polo-like Kinase Inhibitor III | 660868-91-7 | sc-203202 | 500 µg | $109.00 | 1 | |
PPAR-α agonist activating FGF-19 through the PPAR-α pathway. Binds to PPAR-α receptors, leading to downstream activation and expression of FGF-19. | ||||||